SCHEMBL6596247

SCHEMBL6596247

Cc1ccc([N+](=O)[O-])cc1CCBr

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
TDP1 Q9NUW8 3/20 0.56
TSHR P16473 3/20 0.56
CYP3A4 P08684 5/20 0.53
PDE2A O00408 1/20 0.47
PDE5A O76074 1/20 0.47
ALOX15 P16050 1/20 0.47
NFKB1 P19838 1/20 0.47
APEX1 P27695 1/20 0.47
PDE4A P27815 1/20 0.47
BLM P54132 1/20 0.47
PDE1B Q01064 1/20 0.47
PMP22 Q01453 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4D Q08499 1/20 0.47
PDE7A Q13946 1/20 0.47
PDE1C Q14123 1/20 0.47
PDE7B Q9NP56 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.43
ACHE P22303 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16975488 0.86 ALDH1A1 (0.58) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL694999 0.86 ALDH1A1 (0.60) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL30780892 0.86 ALDH1A1 (0.60) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL10340437 0.84 ALDH1A1 (0.58) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL16975448 0.83 ALDH1A1 (0.56) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL14768876 0.82 ALDH1A1 (0.64) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL10175659 0.82 ALDH1A1 (0.64) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL28744999 0.81 ALDH1A1 (0.55) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL5598378 0.81 GSK3B (0.43) ALDH1A1TDP1TSHRCYP3A4HSD17B10
SCHEMBL29001898 0.79 HSD17B10 (0.43) ALDH1A1TDP1TSHRCYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3102194-A1 BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS Quadriga Biosciences, Inc. (US) 2016-12-14 EP disclosed
WO-2015117146-A1 BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS QUADRIGA BIOSCIENCES, INC. (US) 2015-08-06 WO disclosed
CN-101981036-B Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors NOVARTIS AG 2013-09-04 CN disclosed
US-6743809-B2 Indole Derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2004-06-01 US disclosed
EP-1305307-B1 INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS LUNDBECK & CO AS H (DK) 2004-05-06 EP disclosed
US-20030166664-A1 Indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2003-09-04 US disclosed
EP-1305307-A1 INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. Lundbeck A/S (DK) 2003-05-02 EP disclosed
WO-2002008223-A1 INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. LUNDBECK A/S (DK) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166664-A1 Indole derivatives useful for the treatment of CNS disorders DRD2, DRD3, CNR1 ALDH1A1 815/4885TDP1 1971/4885TSHR 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.